AbbVie (ABBV)

Executive Summary

AbbVie is a global biopharmaceutical leader with a $376 billion market capitalization, driven by strong commercial execution of its immunology portfolio, including Skyrizi (risankizumab) and Rinvoq (upadacitinib). These next-generation therapies are successfully offsetting the revenue decline from Humira due to biosimilar competition. With 36 approved products across immunology, oncology, neuroscience, and virology, AbbVie maintains a diversified revenue base. In 2025, Skyrizi and Rinvoq combined sales exceeded $30 billion, supported by label expansions in Crohn's disease, psoriasis, and atopic dermatitis. The company's pipeline includes promising late-stage assets such as emraclidine (CNS) and telisotuzumab vedotin (ADC for NSCLC), positioning AbbVie for sustained growth amid patent expirations.

Upcoming Catalysts (preview)

• Q3 2026Emraclidine Phase 3 readout in schizophrenia60% success
• Q1 2027Telisotuzumab vedotin FDA decision for NSCLC50% success
• Q4 2026Rinvoq label expansion in giant cell arteritis70% success